Navigation Links
QMed, Inc. Receives 2-Year Extension of Medicare Coordinated Care Demonstration Project by CMS
Date:4/7/2008

EATONTOWN, N.J., April 7, 2008 /PRNewswire-FirstCall/ -- QMed, Inc., (Nasdaq: QMED) today announced it has been granted a two year operating extension from the Centers for Medicare and Medicaid Services (CMS) for its Medicare Coordinated Care Demonstration (MCCD) project in Northern California.

In 2002, The CMS selected 15 sites for a pilot project to test whether providing coordinated care services to Medicare fee-for-service beneficiaries with complex chronic conditions can yield better patient outcomes without increasing program costs.

In 2006, the pilot project was extended by CMS for an additional 2 years to QMed and 10 other sites to allow time for further data analyses (4 sites were discontinued).

In December 2007, CMS completed the review of the 4-year evaluation data. As only 3 of the 11 operating sites showed a potential for budget neutrality, CMS offered an extension to QMed (and the 2 other potentially budget neutral sites) for 2 more years to allow further study of the respective programs. The remaining 8 sites will be terminated as scheduled in 2008.

Jane Murray, QMed's president and CEO, said, "Given the political and fiscal sensitivity associated with rising health care costs in the Medicare population, rigorous analysis of randomized trials for coordination of care in the chronically ill is a National mandate to be certain that such approaches are cost-effective and produce quality outcomes. The MCCD pilot, the longest studied randomized Medicare trial of its type, has demonstrated that certain approaches are not cost effective, while others, such as QMed's, may very well be cost effective. Given our proprietary clinical rules engine and unique community-based, provider-facing approach to care coordination, we are very pleased with our outcomes to date and are honored to be one of the three remaining sites selected by CMS. As care coordination of today's Medicare population is so vital to the future of our industry, we look forward to working with CMS in the MCCD and possible future demonstration projects in the years to come."

About the Medicare Coordinated Care Demonstration

MCCD is one of the first studies of chronic care coordination under fee- for-service Medicare. It was designed to test whether care coordination services can lower costs, increase patient satisfaction and improve quality of care for Medicare Beneficiaries with chronic illnesses.

The coordinated care demonstration was authorized by Section 4016 of the Balanced Budget Act of 1997 (BBA). The BBA requires that the projects target chronically ill Medicare fee-for-service beneficiaries that are eligible for both Medicare Parts A and B.

About QMed, Inc.

QMed has developed evidence-based clinical information management systems for use by health plan customers. The QMed systems incorporate Disease Management services to patients and decision support to physicians. The Company's subsidiaries have specialized in serving high-risk populations of Medicare beneficiaries.

Except for historical information contained herein, matters discussed in this news release are forward-looking statements that involve risks and uncertainties. They include but are not limited to those relating to the timely implementation of programs, the impact of business and operational conditions, competitive product introductions, acceptance and pricing, and those risks detailed in the Company's filings with the Securities and Exchange Commission (SEC). Actual results may differ materially from any forward- looking statements due to these risks and uncertainties.

Contact: William Schmitt, QMed, Inc. - 732-544-5544 x1112


'/>"/>
SOURCE QMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Thermo Fisher Scientific Receives FDA Clearance for MRSA Test Medium
2. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
3. DermaGen AB Receives Over 1 Million Euros From a New Share Issue
4. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
5. Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe
6. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
7. Florastor(R) Receives ConsumerLab.com Certification
8. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
9. Vermillion Receives Award From the Society of Gynecologic Oncologists
10. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
11. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $47.6 billion ... estimates and forecasts for all the given segments on global as ...
(Date:2/23/2017)... February 23, 2017 The fast-growing cannabis ... the United States . According to the 2017 Legal ... is expected to create 283,422 jobs by 2020, with an ... the next four years. The accelerating pace of cannabis legalization ... of legal cannabis market, which will further create more business ...
(Date:2/23/2017)... , February 23, 2017 ... on the global market for intraoperative imaging, excerpts ... valued at US$ 513.9 million. According to the ... surging on the grounds of increasing adoption of ... field of diagnostic imaging for neurosurgeries. The world,s ...
Breaking Medicine Technology:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... outlet with a clinician-based audience, will be participating in Rare Disease Day events, ... Washington, D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a national ... marketing, social media management, corporate communications, SEO and cause marketing, is opening an ... nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing ... generations converge and explore the world from different perspectives. By providing a place ... to gain understanding, increase empathy, and find greater happiness. , "Our approach ...
(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
Breaking Medicine News(10 mins):